Avadel Pharmaceuticals plc (AVDL) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Dublin, Ireland. 현재 CEO는 Gregory J. Divis Jr..
AVDL 을(를) 보유 IPO 날짜 1996-06-07, 188 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $2.12B.
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
